• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
GUAN Yuyao,WU Yubao,JI Jingchao,HAN Tongzhou,ZHENG Lei.Efficacy and safety of Donepezil Hydrochloride Tablets in the treatment of dementia: a network Meta-analysis[J].Journal Of Pharmaceutical Research,2025,44(6):618-624[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2378times   Download 772次 QR Code for this article
Scan with your phone!
盐酸多奈哌齐片治疗痴呆有效性和安全性的网状Meta分析
管玉瑶,吴玉保,姬经超,韩同洲,郑磊
Font:Larger+|Default|Smaller-
(山东省立第三医院药学部,山东 济南 250031)
摘要:
目的 运用网状Meta分析系统对国产和进口多奈哌齐治疗痴呆的有效性和安全性进行评估,以期为临床治疗痴呆的药物选择提供可借鉴的可靠依据。方法 通过计算机应用不同的检索策略,使用不同的检索方法,检索PubMed、Embase、Cochrane Library、CNKI、万方数据和中国生物医学文献数据库,收集包含有关国产和进口多奈哌齐治疗痴呆的随机对照试验(RCT),检索时间范围为1996年1月—2024年1月,研究人员独立地筛选文献、提取数据和评介研究的偏倚风险,并使用Stata 17.0软件进行网状Meta分析。结果 共纳入研究34项,涉及3 432例患者。网状 Meta 分析结果显示,国产多奈哌齐(累积排序曲线下面积SUCRA为0.983)治疗痴呆的疗效优于进口多奈哌齐SUCRA为0.748),进口多奈哌齐(SUCRA为0.855)的MMSE评分优于国产多奈哌齐(SUCRA为0.640),进口多奈哌齐(SUCRA为0.537)不良反应发生率相比国产多奈哌齐(SUCRA为0.499)略低。结论 现有证据表明,进口多奈哌齐较国产多奈哌齐在疗效和安全性方面总体相似,但因受当前研究数量和质量的限制,还需要更多高质量、大样本研究来验证这一结论。
关键词:  痴呆  多奈哌齐  网状Meta分析  随机对照试验
DOI:10.13506/j.cnki.jpr.2025.06.017
基金项目:山东省自然科学基金资助项目(No.ZR2022MH250);山东省药品临床综合评价项目(No.2022YZ027);山东省医学会临床科研资金齐鲁专项(No.YXH2022ZX02050);山东省医药卫生科技项目(No.202313010259、202413050441)
Publication Date:June 25, 2025
Efficacy and safety of Donepezil Hydrochloride Tablets in the treatment of dementia: a network Meta-analysis
GUAN Yuyao,WU Yubao,JI Jingchao,HAN Tongzhou,ZHENG Lei
(Department of Pharmacy, Shandong Provincial Third Hospital, Jinan 250031, China)
Abstract:
Objective To assess the effectiveness and safety of both domestic and international donepezil in treating dementia via a network meta-analysis, offering a more dependable guide for clinical medication choices in managing dementia.Methods An extensive search was performed across PubMed, Embase, Cochrane Library, CNKI, WanFang Data, and CBM databases to gather randomized controlled trials (RCTs) that evaluated domestic versus imported donepezil for dementia treatment, covering the period from January 1996 to January 2024.Two investigators separately reviewed the literature, collected data, and evaluated the potential for bias in the studies considered. A network meta-analysis was conducted utilizing Stata 17.0 software.Results 34 studies with a combined total of 3,43 participants were included. The outcomes of the network meta-analysis indicated that domestic donepezil (Surface Under the Cumulative Ranking curve, SUCRA =0.983) was more effective in treating dementia than imported donepezil (SUCRA =0.748). However, imported donepezil (SUCRA =0.855) showed better MMSE scores than domestic donepezil (SUCRA =0.640). The incidence of adverse reactions was slightly lower with imported donepezil (SUCRA =0.537) compared to domestic donepezil (SUCRA =0.499).Conclusion Current evidence suggests that the overall efficacy and safety of imported and domestic donepezil are similar.Nonetheless, because the quantity and caliber of the studies included are restricted, additional large-scale, high-quality research is necessary to confirm these results.
Key words:  Dementia  Donepezil  Network meta-analysis  Randomized controlled trial
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.